Introduction
The Philadelphia chromosome was the ®rst consistent chromosomal abnormality linked to a speci®c human cancer, chronic myeloid leukemia (CML) (Nowell and Hungerford, 1960) . CML accounts for 15 ± 20% of human leukemia (Ghaari et al., 1999) . CML is a clonal disorder originating in the hematopoietic stem cell (HSC) (Delforge et al., 1999; Fialkow et al., 1967 Fialkow et al., , 1977 Holyoake et al., 1999; and reviewed in Kabarowski and Witte, 2000; Raskind and Fialkow, 1987; Takahashi et al., 1998; Yoe et al., 1987) . It can be regarded as a biphasic disease (reviewed in Clarkson et al., 1997) . The ®rst stage, chronic phase (cpCML), is characteristically indolent with clinical features including a large increase in the number of myeloid precursors and their progeny. Numbers of mature neutrophils as well as basophils and eosinophils are elevated in the blood. In the bone marrow there is also an increase in the ratio of myeloid to erythroid cells. Splenomegaly, hepatomegaly and mild anemia are common. In the blast crisis phase, blood and marrow mature cells are displaced by immature blasts. More than 50% of patients enter a myeloid blast stage resembling acute myeloblastic leukemia (AML). A pre-B blast stage similar to acute lymphoid leukemia (B-ALL) accounts for 30% of patients, and erythroid blasts develop in 10% of patients. Rarely do T cell blasts (T-ALL) evolve (Colleoni et al., 1996; Fabbiano et al., 1998) . During progression to blast phase, over 80% of patients develop additional chromosome abnormalities (reviewed in Mitelman, 1993) . This suggests that genetic aberrations in addition to the Ph chromosome are necessary for chronic phase CML to develop to blast crisis.
The Ph chromosome results from a reciprocal translocation, between chromosomes 9 and 22 t(9;22)-(q34;q11) (Nowell and Hungerford, 1960; Rowley, 1973) . The telomeric segment of chromosome 9q34 encoding the ABL tyrosine kinase gene is fused to the centromeric segment of chromosome 22q11 encoding the BCR gene (see Figure 1 ). This forms a chimeric BCR ± ABL mRNA and protein product. The alternative reciprocal translocation product, ABL ± BCR, is thought not to play a role in leukemogenesis and will not be discussed further (Lazaridou et al., 1994; Melo et al., 1993 Melo et al., , 1996 . Depending on the breakpoint positions within the BCR and ABL genes, dierent forms of BCR ± ABL are generated. Most breakpoints within ABL occur between exons 1a and 1b to generate BCR ± ABL mRNA with BCR sequences fused to ABL exon a2. Breakpoints within the BCR locus occur over a large area spanning over 20 exons. Three breakpoint cluster regions (bcr) within BCR are most frequently involved. The major breakpoint cluster region (M-bcr) generates an mRNA product with either a b2a2 or b3a2 junction due to alternative splicing which encodes a 210 Kd chimeric protein p210 BCR ± ABL (Ben-Neriah et al., 1986; Heisterkamp et al., 1985; Konopka et al., 1984; Shtivelman et al., 1985) . A minor breakpoint cluster region (m-bcr) junction in BCR produces a smaller 185/190 Kd chimeric protein (Chan et al., 1987; Clark et al., 1987; Fainstein et al., 1987; Walker et al., 1987) . Recently, a larger 230-kd chimeric protein P230 BCR ± ABL has been identi®ed generated from a gbcr breakpoint (Saglio et al., 1990) .
Other fusion events leading to expression of activated forms of ABL occur in leukemia. Rare cases of human ALL express a TEL ± ABL fusion (Golub et al., 1996; Papadopoulos et al., 1995) . In mice, the original viral form of ABL (GAG ± ABL) is a chimeric protein in which sequences encoding the ®rst exon and part of the second exon (a2) of ABL are replaced by those encoding the viral GAG protein. GAG ± ABL is associated with B-ALL as well as other leukemias (reviewed in Rosenberg and Witte, 1988) .
Oncogenic forms of ABL have highly elevated levels of tyrosine kinase activity compared to c-ABL. The tyrosine kinase activities of GAG ± ABL, P185 BCR ± ABL and P210
BCR ± ABL correlate with their transformation potencies in several systems (Lugo et al., 1990) . Tyrosine kinase inactive mutants of BCR ± ABL and GAG ± ABL lose their transforming potential (Engelman and Rosenberg, 1987; Pendergast et al., 1993a; Ponticelli et al., 1982; Witte et al., 1980 Witte et al., , 1981 . These ®ndings have supported the essential role of deregulated tyrosine kinase activity in transformation by ABL oncogenes, a factor exploited by the ABL kinase inhibitor STI571, a 2-phenylaminopyrimidine that speci®cally inhibits the tyrosine kinase activity of ABL, PDGF, and C-KIT (Buchdunger et al., 1995) . Phase 1 clinical trial studies of Ph + chronic phase CML patients treated with STI571 have demonstrated its ecacy, with 98 ± 100% complete hematologic remission (Druker et al., 2001) .
In addition to the tyrosine kinase domain, BCR ± ABL contains oligomerization Muller et al., 1991) SH2 (Afar et al., 1994; Goga et al., 1995) , autophosphorylation (Pendergast et al., 1993a) , actin binding Wang, 1991, 1993; Van Etten et al., 1994) , and DNA binding (Kipreos and Wang, 1992 ) motifs important for transformation (see Figure 1) . The oligomerization domain of BCR ± ABL is essential for transformation (Maru et al., 1996a; . Other domains such as the Grb2 binding site are required for transformation of ®broblasts to anchorage independence (Pendergast et al., 1993b) but not of hematopoietic cell lines to growth factor independence (Cortez et al., 1995) . In vivo leukemogenesis studies are important to determine the signi®cance of these BCR ± ABL domains.
There is strong association of the three main forms of BCR ± ABL with speci®c types of human leukemias. P210 BCR ± ABL is generally considered as the pathognomonic marker of CML and is also associated with approximately one third of adult Ph + ALLs (Deininger (Kantarjian et al., 1991) and myeloma (Martiat et al., 1990) . P185 BCR ± ABL is linked to the remaining two-thirds of Ph + ALL cases not associated with P210 BCR ± ABL (Kantarjian et al., 1991; Melo, 1996; Secker-Walker et al., 1988) . In addition, P185 BCR ± ABL is linked to 3% of atypical CML cases with monocytosis , and in some AML cases (Kurzrock et al., 1987) and lymphoma (Mitani et al., 1990) . The recently identi®ed P230 BCR ± ABL is mainly associated with neutropenic CML (Pane et al., 1996) as well as some cases of CML (Wilson et al., 1997) . It is not understood why dierent forms of BCR ± ABL are preferentially associated with distinct leukemias. Differences in target cell as well as BCR ± ABL form are possible explanations.
A correlation between the type of leukemia formed and the speci®c target cell containing the Ph chromosome is evident in human patients. In CML patients the Ph chromosome is present in a quiescent hematopoietic stem cell (HSC) population Delforge et al., 1999; Holyoake et al., 1999; reviewed in Kabarowski and Witte, 2000) . The Ph + quiescent HSC is often maintained in CML patients treated with irradiation and bone marrow transplantation (Deisseroth et al., 1994; Diekmann et al., 1994) and is likely the cause of disease recurrence. In most cases of Ph + ALL, on the other hand, the presence of the Ph chromosome is restricted to the lymphoid lineage (Haferlach et al., 1997; Kasprzyk et al., 1999) . Although some cases of Ph + ALL are associated with the presence of the Ph chromosome in multiple lineages, suggesting HSC origin, many of these cases may represent CML lymphoid blast crises following a clinically silent/undiagnosed chronic phase (Pajor et al., 2000) .
Retroviral transduction of bone marrow cells with ABL oncogene
In 1970, Abelson and Rabstein showed that mice infected with Abelson murine leukemia virus reproducibly generated B cell lymphomas (Abelson and Rabstein, 1970) . It was later demonstrated that GAG ± ABL was the essential etiological component. GAG ± ABL can also transform mast cells and generate plasmacytomas in vivo (reviewed by Rosenberg and Witte, 1988) . Abelson and Rabstein (1970) tested if alternative strains of mice were equally susceptible to virus induced lymphoma. Although all strains of mice developed the same type of B cell lymphoma, the disease latency varied between strains, demonstrating that genetic context can vary the susceptibility to disease establishment. Do dierent strains of mice vary in their penetrance to P210 induced leukemia? Elefanty and Cory (Elefanty et al., 1990) tested two mouse strains, DBA/2 and C57BL/6. DBA/2 mice reconstituted with P210 transduced bone marrow developed macrophage tumors 80% of the time. However, C57BL/6 mice only had a 16% incidence of macrophage tumors, and a much higher incidence of erythroid leukemia. Neither strain developed a CML-like disease (see Table 1 ).
In 1990, several groups demonstrated that P210 can induce a CML-like disease in mice (Daley et al., 1990; Kelliher et al., 1990) . The experimental strategy was to enrich for HSC expression of P210. Mice were treated with 5-FU to kill cycling cells and enrich for HSC populations. Quiescent HSCs are induced to cycle with cytokine mixtures prior to infection with retroviral vectors expressing P210. Reconstitution of lethally irradiated BALB/c mice with P210 infected cells generated a CML-like disease.
This retroviral transduction system generated a CML-like disease in 20 ± 30% of reconstituted BALB/c mice with a mean disease latency of 63 days (Daley et al., 1990; Kelliher et al., 1990 ) (see Table 1 ). P210 also induced lymphoid leukemias/lymphomas and monocytic/macrophage tumors in recipient mice. Clinical features of CML mice included high white blood cell counts (WBC) with elevated levels of granulocytes, hypogranulated basophils and metamyelocytes in the blood. The bone marrow was hypercellular with a dominance of myeloid cells at all stages of development. The spleen and liver were enlarged with leukemic in®ltrates. This CML-like disease was transplantable, suggesting the initial leukemic clone was of stem cell origin (Daley et al., 1990) .
Could this CML model system be used to study the progression of CML disease from chronic phase to blast crisis? Gishizky et al. (1993) studied the development of P210 induced leukemia in primary, secondary, tertiary and quaternary transplant recipients. In primary recipients, three types of leukemia, B lymphoid, myelo/monocytic, and granulocytic leukemia resembling chronic phase CML, developed with a wide range in latency. The leukemias were categorized into short (5140 days) and long (4140 days) latency (see Table 1 ).
The question of whether the short and long latency leukemias originate from dierent target cells was tested.`Early' and`late' leukemic mouse bone marrow samples were tested by secondary transplantation. Myelo/monocytic and B lymphoid leukemias were equally transplantable from`early' and`late' leukemic mice, suggesting that P210 induced B-ALL and myelo/ monocytic leukemia may arise from both transduced HSCs and committed progenitors.
However,`early' and`late' CML disease were not equally transplantable. Only one out of 30 secondary recipients transplanted with`early' CML donor cells developed leukemia (see Table 1 ). In sharp contrast, late' CML disease was readily transplantable in 75% of secondary recipients (see Table 1 ). The transplanted chronic phase CML disease progressed to blast crisis in the majority of secondary recipients. Acute myelo/ monocytic blast stage (AMML) was the predominant disease, but chronic phase CML, B-ALL and T-ALL also occurred (see Table 1 ). Clonal analyses revealed that leukemic cells from dierent blast crises had the same P210 viral integration site as the initial chronic Chung et al. (1996) noticed some mice did not develop leukemia after transplantation with GAG ± ABL infected bone marrow cells. This group questioned whether GAG ± ABL expression in HSCs was silenced in these mice. Reconstituted mice that did not develop leukemia were treated with 5-FU to activate quiescent HSC carrying a GAG ± ABL integrant. The bone marrow was transplanted into secondary recipients, which developed a CML-like leukemia. The leukemia arose from a dierent infected GAG ± ABL clone than that from which the primary leukemia developed. This demonstrated that activating a quiescent HSC which harbored an oncogenic form of ABL could generate a CML-like disease. CML patients treated with irradiation have most of their Ph + cells destroyed. The cause of relapse in these patients is most likely the presence of radiation resistant Ph + quiescent HSCs which become re-activated to generate CML (Deisseroth et al., 1994; Diekmann et al., 1994; Holyoake et al., 1999) .
As mentioned earlier, there is a strong correlation between BCR ± ABL form and disease phenotype in Ph + human leukemias. However, a third of Ph + B-ALL involve the P210 form of BCR ± ABL. Although these cases may not represent true de novo B-ALLs but rather B-lymphoblastic blast crisis following an undiagnosed chronic phase, it poses the question of whether the structure of BCR ± ABL or the target cell acquiring the Ph translocation and BCR ± ABL expression are most critical in determining the type of leukemia formed. Kelliher et al. (1990 Kelliher et al. ( , 1991 addressed this issue by infecting the same 5-FU treated target cell population with GAG ± ABL, P185 or P210. They observed that all forms of oncogenic ABL were capable of generating a similar spectrum of disease: Pre-B lymphomas, myeloid leukemias and B leukemias. Scott et al. (1991) disagrees with this conclusion. This group observe that GAG ± ABL induced leukemias generated by a similar method are associated with less severe splenomegaly and architectural disruption compared to that observed in P210 induced leukemias. GAG ± ABL leukemic mice develop paraspinous masses which do not occur in P210 generated leukemias. In addition, GAG ± ABL expression is only detected in leukemic monocytes and lymphoid cells, but not granulocytes. Clark et al. (1993) tested whether GAG ± ABL, P185, and P210 are equally capable of generating thymomas. This group injected GAG ± ABL, P185, or P210 virus directly into thymic lobes. All three forms of oncogenic ABL induced indistinguishable thymomas. These ®ndings further support the hypothesis that target cell type may primarily determine the leukemic phenotype.
A disadvantage of the CML animal model described above is the long disease latency and low penetrance. Advances in retroviral transduction and hematopoietic expression have led to the development of new models which develop leukemia with 100% penetrance and a short latency period of 18 ± 30 days. Critical improvements in retroviral transduction protocols include more eective infection protocols and use of the MSCV LTR promoter engineered for high expression in immature hematopoietic cells (Hawley et al., 1994) . The MSCV BCR ± ABL leukemia model retains the use of 5-FU treatment to enrich for HSC populations, and BALB/c mice as a highly penetrant host environment. A comparison of BALB/c and C57BL/6 strains for susceptibility to P210 induced CML-like disease showed 100% penetrance with BALB/c and 50% penetrance with C57BL/6 (Li et al., 2001) .
Several groups have demonstrated the generation of CML-like disease in P210 MSCV retroviral mouse models (Li et al., 1999; Pear et al., 1998; Zhang and Ren, 1998) . The clinical features of the disease in this animal model include elevated white blood cell counts, with a dominance of mature granulocytes and the presence of metamyelocyes and nucleated erythroid cells. Splenomegaly and hepatomegaly occur with an in®ltration of immature and mature granulocytes. The bone marrow is hypercellular with a predominance of granulocytes. The disease is polyclonal with an average of seven clones dominating leukemic progression. The CML-like disease is transplantable to secondary and tertiary recipients. The transplanted disease is monoclonal and can develop to a T lymphoblastic blast crisis (T-ALL) in quaternary recipients. However, T-ALL blast crisis is rare in human CML. Another unusual characteristic of this model is death from pulmonary hemorrhage, not common in human CML, which the authors suggest could be due to a rapid development of leukostasis, blast/basophilic degranulation, or platelet dysfunction.
The high reproducibility of a chronic phase CML blood picture and short latency period in this MSCVbased system has enabled researchers to address many questions regarding BCR ± ABL induced leukemia. Li and Van Etten used this system to test whether the three forms of BCR ± ABL (P185, P210 and P230) generate identical or dierent leukemias. All three forms of BCR ± ABL induced a CML-like disease with 100% penetrance (Li et al., 1999) . This again supports the hypothesis that the target cell expressing BCR ± ABL, rather than the BCR ± ABL form, may be most critical in determining the type of leukemia. However, the short disease latencies (21 days for P185, 23 days for P210 and 25 days for P230) precluded the establishment of whether these dierent BCR ± ABL forms induce more or less aggressive leukemias. Testing potential BCR ± ABL signaling pathways using retroviral transduction
Loss of P53 function is a common event in the development of multiple human malignancies (reviewed by Hupp et al., 2000; Soussi, 2000) including 30% of human CML blast crises (Prokocimer and Rotter, 1994; Rovira et al., 1995) . Several groups have studied the role of P53 in BCR ± ABL and GAG ± ABL induced leukemia. A CML model using 5-FU treated donor bone marrow cells retrovirally transduced with P210 to reconstitute lethally irradiated mice was utilized. Mice reconstituted with P53 transduced knock-out cells developed a more aggressive myeloblastic leukemia with shorter latency compared to those reconstituted with transduced wild-type cells (Skorski et al., 1996) . In human CML, loss of P53 function is preferentially associated with progression to myeloid rather than lymphoid blast crisis leukemia (Prokocimer and Rotter, 1994) . Over 40% of Pre-B cells transformed by GAG ± ABL harbor a P53 mutation (Thome et al., 1997) . GAG ± ABL lymphoma studies also demonstrate a faster rate of disease progression in the absence of P53 (Unnikrishnan et al., 1999; Zou et al., 2000) . In addition, 75% of GAG ± ABL lymphomas in P53 heterozygous (P53 +/7 ) mice had lost function of the remaining P53 allele. It is clear that multiple genetic alterations may determine the severity of disease phenotype.
Many pathways have been implicated as being important for BCR ± ABL induced transformation. One is the IL-3 signaling pathway. BCR ± ABL expression in IL-3 dependent cell lines confers IL-3 independence (Anderson and Mladenovic, 1996; Hariharan et al., 1988) . Human Ph + CML cells have been shown to have a reduced requirement of IL-3 for in vitro . The MSCV P210 driven CML model has demonstrated an elevation in IL-3 levels in CML mice (Zhang and Ren, 1998) . BCR ± ABL binds to the common subunit of the IL-3 receptor (IL-3RBc) and lead to its phosphorylation (Wilson-Rawls et al., 1996) . Mice reconstituted with constitutively active forms of IL-3RBc transduced bone marrow develop a myeloproliferative disorder and leukemia (McCormack and Gonda, 1999) .
5-FU treated IL-3 de®cient murine bone marrow cells transduced with P210 retroviruses have been used to reconstitute mice. P210 transduced wild-type and IL-3 7/7 bone marrow cells were equally eective at generating CML disease in reconstituted mice (Li et al., 2001) . To address whether IL-3 is required in the bone marrow environment, as opposed to the P210 target cell, wild-type or IL-3 7/7 mice were used as recipients. P210 induced leukemia with similar latencies irrespective of recipient genotype. However, an interesting observation was noted. When both donor cells and recipient were IL-3 7/7 , the leukemic mice had an elevated level of monocytes and macrophages in the blood. Interestingly, in rare cases of human CML associated with P185, monocytosis is frequently observed. In the absence of IL-3, P210 generates an atypical CML picture similar to human monocytic CML induced by P185. Nevertheless, the issue of whether development of BCR ± ABL induced CML-like disease in this system involves, and perhaps requires, the IL-3RBc itself remains to be addressed.
Many groups have shown that STAT5 activation correlates with BCR ± ABL transformation (reviewed by Sattler and Salgia, 1997) . Expression of a dominant negative form of STAT5 inhibited BCR ± ABL induced bone marrow transformation in vitro (NieborowskaSkorska et al., 1999). Moreover, a dominant negative form of STAT5 inhibited both BCR ± ABL induced IL-3 independent growth and leukemogenesis of 32D cells (Nieborowska-Skorska et al., 1999) . However, studies with STAT5A/B knock-out cells clearly demonstrate that P210 and P185 do not require STAT5A/B for leukemogenesis (Sexl et al., 2000) . This result exempli®es the importance of using alternative genetic approaches to de®nitively address the requirement of speci®c pathways in BCR ± ABL oncogenesis.
BCR ± ABL expression is linked in cis to GFP expression via an internal ribosomal entry site (IRES) element in the MSCV BCR ± ABL retrovirus. Several groups have demonstrated that expression of GFP in this system is an accurate indicator of BCR ± ABL expression (Li et al., 1999; Pear et al., 1998; Zhang and Ren, 1998) . The eect of enforced expression of a candidate gene, or its dominant negative counterpart, upon BCR ± ABL induced leukemogenesis can be tested by appropriate replacement of GFP sequences.
Other animal model systems with a longer disease latency and lower penetrance may be better suited to identify genes that enhance BCR ± ABL induced leukemia. Afar et al. (1997) generated leukemia in 25% of animals reconstituted with P185 transduced bone marrow between 30 and 90 days. Rin-1 has been shown to bind BCR ± ABL and synergize with BCR ± ABL in in vitro transformation studies (Afar et al., 1997) . The complementing activity of Rin-1 was tested in this mouse model. Co-expression of Rin-1 with P185 decreased the latency of Pre-B leukemia and increased its penetrance from 25 to 60% (Afar et al., 1997) . In Ph + human cell lines, BCR ± ABL associates with Rin-1 and leads to Rin-1 phosphorylation (Afar et al., 1997) .
BCR ± ABL domain requirement studies
There are examples where domains of BCR ± ABL shown to be critical for transformation in vitro have also been demonstrated as essential for induction of leukemia. An oligomerization mutant of BCR ± ABL (BCR ± ABLD61) lacking the ®rst 61 amino acids of BCR cannot induce CML-like disease in the MSCV P210 transduction system (Zhang et al., 2001a) . Surprisingly, this P210 mutant generates a T cell leukemia/lymphoma with a long latency of 115 days. These results support in vitro studies (Maru et al., 1996b; Muller et al., 1991; Tauchi et al., 1998) demonstrating that the oligomerModels of Ph + leukemias S Wong and ON Witte ization domain is critical for BCR ± ABL transformation and suggest that the BCR oligomerization domain may be a potential therapeutic target. The role of the SH3 domain in BCR ± ABL oncogenesis is controversial. A deletion of the SH3 domain in P210 BCR ± ABL (P210DSH3) delays the latency of leukemias developing in mice inoculated with expressing 32D cells from 6 ± 9 weeks to 17 ± 45 weeks (Skorski et al., 1998) . However, deletion of the SH3 domain potentiates BCR ± ABL transformation of Rat1 ®broblasts to anchorage independence (Maru et al., 1996b) . Does the SH3 domain potentiate or inhibit BCR ± ABL induced leukemogenesis? To address this question, P210DSH3 was compared to wild-type P210 for leukemogenic potential in the 5-FU, MSCV retroviral transduction system. Deletion of the SH3 domain did not alter the leukemogenic potential of P210 with respect to both latency and disease phenotype (Gross et al., 1999) . Although only two Ph + patients harboring an SH3 domain deleted form of P210 have been reported, neither showed distinguishing clinical features (Tiribelli et al., 2000) . These results suggest that the SH3 domain may not signi®cantly in¯uence BCR ± ABL induced leukemogenesis.
Limitations of the MSCV retroviral CML model have been revealed in studies of SH2 domain point/ deletion mutants of BCR ± ABL (P210DSH2). Two groups have observed dierent disease phenotypes in mice reconstituted with bone marrow transduced with retroviruses encoding P210DSH2. One group observed that P210DSH2 mice develop a CML-like myeloproliferative disease with a longer latency compared to wild-type P210 mice (Zhang et al., 2001b) . The CML-like disease was also distinct from that induced by P210 WT; a pre-leukemic stage with an expansion of mature and immature B-cells occurred prior to onset of a CML-like disease. Another group showed that P210DSH2 mice develop mainly B-ALL with a long disease latency compared to wild-type P210 (Roumiantsev et al., 2001) . There is no obvious explanation for the dierent phenotypes observed from both groups.
Generation of transgenic mice expressing BCR ± ABL
Three main approaches have been taken to generate transgenic mice expressing BCR ± ABL.
(1) Use of global promoters driving BCR ± ABL expression. (2) Hematopoietic restricted expression of BCR ± ABL. (3) Regulatable expression of BCR ± ABL.
Global promoter driven BCR ± ABL expression
The ®rst generation of transgenic models tested global promoters to drive P210 and P185 BCR ± ABL expression in mice. One obvious choice of promoter to test was the mouse bcr promoter. This would conceivably mimic aspects of BCR ± ABL transcriptional regulation in the human disease. Bcr P210 transgenic embryos failed to develop (Heisterkamp et al., 1991) . However, using the Methallothienin (MT) promoter, both P210 and P185 founder animals were obtained. MT P185 transgenic lines develop B-ALL (Heisterkamp et al., 1990; Voncken et al., 1992a Voncken et al., , 1995a with an expansion of Pre-B lymphoblasts in hematopoietic organs such as the bone marrow and spleen. Non-hematopoietic organs including brain, heart, and muscle also expressed P185 but appeared unaected. The Pre-B leukemias were oligoclonal and transplantable. Two groups generated MT promoter driven P210 transgenic lines with dierent outcomes. MT P210 transgenics generated by Voncken et al. (1995a) developed B-ALL in 30% of cases (latency 100 ± 200 days), 60% developed T-ALL (latency 130 ± 300 days) and 7% developed myeloblastic leukemia by 380 days. MT P210 mice generated by Honda et al. all developed T cell leukemia within 90 days (Honda et al., 1995) . One notable dierence between the two MT P210 transgenic lines is the mouse strain background (see Table 1 ), again demonstrating the importance of genetic context.
Hematopoietic lineage restricted promoters driving BCR ± ABL expression
To restrict BCR ± ABL expression to the hematopoietic system the tec promoter has been employed to drive BCR ± ABL expression preferentially in hematopoietic precursors (Mano et al., 1990) . Tec promoter driven P210 founders develop clonal T cell thymomas with 100% penetrance (Honda et al., 1998) . It is interesting to note that the strain of these founders is C57BL/ 66DBA/2F2, which is also associated with the preferential development of T cell leukemias in MT promoter driven P210 founders (see Table 1 ).
A transgenic line derived from a tec promoter driven P210 founder, however, developed a CML-like disease at 1 year of age (Honda et al., 1998) . These mice develop an indolent disease with elevations in platelet count and mature granulocytes at 5 ± 8 months of age. At one year of age, these mice succumb to a clonal chronic phase CML-like disease. The tec promoter driven P210 transgenic is the only transgenic line that routinely succumbs to a CML-like disease. The disease latency in these mice is extremely long; during the ®rst year of life (pre-leukemic phase), P210 expression cannot be detected at the protein level in these mice. However, a low level of P210 expression is detectable by RT ± PCR, suggesting that low levels of P210 expression may underlie the long latency of disease in this model.
Regulatable promoter driving BCR ± ABL expression
To control the level and timing of P210 BCR ± ABL expression in an adult mouse, a tetracycline regulatable system has been employed. Crossing mouse mammary tumor virus (MMTV) promoter driven Tet-transact- ivator transgenic mice with Tet-responsive promoter driven P210 transgenic mice generated doubly transgenic mice. These compound transgenic mice were highly responsive to Tet-regulated expression of P210 by administration and removal of tetracyline from drinking water (Huettner et al., 2000) . In response to P210 expression these mice develop B-ALL within 24 ± 80 days. Sustained P210 expression was required for the maintenance of P210 induced B-ALL, as shutting down BCR ± ABL expression resulted in disease remission. Previously, a requirement for sustained BCR ± ABL expression in the maintenance of the transformed state had only been demonstrated in cell lines expressing temperature sensitive forms of BCR ± ABL or GAG ± ABL proteins (Cleveland et al., 1989; Engelman and Rosenberg, 1990; Kabarowski et al., 1994) . This suggests that despite the association of Ph + disease progression with the acquisition of additional genetic mutations, a requirement for BCR ± ABL tyrosine kinase is retained. This is also re¯ected in human chronic phase CML, where blocking the tyrosine kinase activity of P210 by STI571 treatment leads to disease remission (Druker et al., 2001) . The Tet regulatable P210 transgenic mouse model does not develop a CML-like disease. P210 expression is only detected in Pre-B cells in these animals, possibly accounting for the sole development of B-ALL. The authors suggest that the MMTV promoter controlling expression of the Tet-transactivator may not be active in HSCs. Use of alternative HSC speci®c promoters and/or enhancers in combination with this Tetregulated system may generate a regulatable CML mouse model.
Studies using the MT P185 transgenic line
In human CML, progression from chronic phase to blast crisis involves a non-random selection of cytogenetic alterations (reviewed by Mitelman, 1993) . Karyotype analyses in preleukemic MT P185 mice showed no detectable chromosomal aberration (Voncken et al., 1992b) . Leukemic mice, however, had a high frequency (88%) of aneuploidy (Voncken et al., 1992b) . Trisomy of chromosomes 10, 12, 14 and 17 were most common in this mouse model (Voncken et al., 1992b) . A comparison of chromosomal abnormalities in human Ph + leukemia with these using the complete human genome sequence and soon complete mouse genome sequence may expand the list of candidate gene clusters or even validate further studies of genes already identi®ed in BCR ± ABL transformation/leukemogenesis systems.
BCR ± ABL expression has been shown to inhibit apoptosis in growth factor dependent cell lines (Amarante-Mendes et al., 1998; Bedi et al., 1995; Cambier et al., 1999; Cortez et al., 1995; Kabarowski et al., 1994; Zhao et al., 2001) . However, an antiapoptotic function of BCR ± ABL in cpCML is controversial (Kabarowski and Witte, 2000) . No signi®cant dierence in apoptosis was observed between normal mice, pre-leukemic mice, or Pre-B-ALL MT P185 transgenic mice (Salloukh et al., 2000) . In addition, Ph + human leukemic Pre-B-ALL cells exhibit normal apoptotic responses to ionizing radiation (Li et al., 1994) . These observations suggest that a major inhibition of apoptosis may not be instrumental in P185 induced B-ALL.
Expression of dominant negative RAS or other dominant negative proteins in the RAS pathway such as c-JUN inhibit BCR ± ABL transformation of ®broblasts in vitro (Pendergast et al., 1993b) and (Raitano et al., 1995; Sawyers et al., 1995; Skorski et al., 1994) . Active RAS requires farnesylation of the RAS CAAX box and localization to the plasma membrane. Inhibition of the RAS pathway using the farnesyl transferase inhibitor SCH66336 has been tested as a potential therapeutic approach in B-ALL. Administration of SCH66366 at a dose of 40 mg/kg prevented development of leukemias in 80% of P185 transgenic mice (Reichert et al., 2001) . Disease free MT P185 mice appeared to maintain normal hematopoiesis with no signs of leukemic blasts during the 200 day observation period. In primary human cells, the farnesyl transferase inhibitor SCH66336 selectively inhibits hematopoietic colony formation of Ph + cells (Peters et al., 2001) . Although inhibition of RAS function is likely to have deleterious eects, low doses of SCH66336 may selectively target BCR ± ABL expressing cells and suppress leukemic cell expansion. Further studies in animal model systems such as the tec promoter driven P210 transgenic line which develop exclusively CML-like disease are perhaps warranted.
Generation of knock-in mice expressing BCR ± ABL from the mouse bcr locus To more accurately mimic P185 expression in human Ph + B-ALL, P185 knock-in mice expressing P185 from the endogenous murine bcr locus were generated. By 4 months of age, 95% of chimeric mice expressing one P185 allele and one normal bcr allele developed Pre-B-ALL (Castellanos et al., 1997) . Pre-B cells dominated the majority of WBCs in the blood and in®ltrated the spleen and liver in leukemic mice. BCR ± ABL expression was detected in the spleen, bone marrow and thymus, but no leukemic involvement was detected in the thymus. The 94% transplantability of this disease suggests the leukemic clone(s) is of stem cell origin. It will be of interest to compare leukemias induced by other forms of BCR ± ABL using this bcr knock-in strategy.
The BCR protein is phosphorylated by BCR ± ABL and is present within BCR ± ABL oligomers Lu et al., 1993; Voncken et al., 1995b) . To test whether BCR is required for P185 induced Pre-B-ALL, P185 knock-in ES cells were ablated of their second bcr allele and used to generate chimeric mice. A comparison of chimeric mice expressing P185 and BCR or P185 alone, did not show any dierence in leukemic penetrance, latency, or phenotype. MT P185 bcr null transgenic mice also produce leukemia with indistinguishable latency and clinical pattern compared to genetically matched MT P185 transgenic counterparts (Voncken et al., 1998) . Together, these observations suggest that a functional bcr gene product may not play a role in the development of P185 associated leukemias.
Knock-outs with CML phenotype
Interferon consensus sequence binding protein (ICSBP) knock-out mice develop a CML-like disease ICSBP is a transcription factor of the interferon regulatory factor (IRF) family, members of which regulate interferon (IFN) stimulated gene expression (Driggers et al., 1990) . ICSBP is poorly active at regulating gene expression by itself (Eklund et al., 1998; Eklund and Kakar, 1999; Sharf et al., 1995) but is highly active when bound to IRF-1 or IRF-2 and PU.1 (Eklund et al., 1998; Eklund and Kakar, 1999) . IFNa treatment leads to remission in chronic phase CML patients (Gutterman, 1994) . It is tempting to speculate therefore that lack of ICSBP predisposes animals to the development of a CML-like disease by altering the balance between active and inactive IRF complexes.
The CML-like disease which develops in ICSBP knock-out mice evolves to a blast stage leukemia. The chronic phase disease is 100% penetrant by 10 ± 16 weeks of age, and by 50 weeks of age, 33% of the mice develop blast stage disease (Holtschke et al., 1996) . The chronic stage disease in these mice is characterized by an elevation of neutrophils in hematopoietic tissues. Development of blast crisis is associated with a huge expansion of myeloblasts in the bone marrow and spleen. B lymphoblasts are dominant in the blood and lymph nodes. ICSBP +/7 mice have a lower penetrance of CMLlike disease compared to ICSBP 7/7 mice, suggesting that development of CML by loss of ICSBP expression is dose-dependent. This would be expected if the critical role of ICSBP is in conjunction with other transcriptional regulators (IRF-1, IRF-2, PU.1) within multi-protein complexes. The ability of ISCBP overexpression to suppress P210 induced CML was examined by expressing ICSBP and P210 in the same MSCV driven bicistronic retroviral vector (Hao and Ren, 2000) . Although leukemic progression in mice reconstituted with P210 transduced bone marrow is associated with a reduction in ICSBP expression, enforced ICSBP expression did not block P210 induced leukemia. However, the latency to leukemic development was increased from 3 to 5 weeks. Several possibilities can explain these apparently contradictory ®ndings. The most obvious is that ICSBP functions as part of a multiprotein complex and overexpression of ISCBP as well as its partner(s) may be necessary to inhibit P210 leukemogenesis. This has been shown in the myelomonocytic cell line U937, in which transfection of all three components (ICSBP, IRF-1 and PU.1) was required to produce a highly active transcriptional complex (Eklund et al., 1998) . Another plausible explanation is that ISCBP downregulation is a consequence of P210 induced myeloid cell expansion rather than a direct eect of BCR ± ABL expression instrumental in the leukemogenic process.
Lack of JunB expression in the myeloid lineage generates a CML-like disease in mice JunB expression increases during myeloid dierentiation (Lord et al., 1993; Mollinedo et al., 1991) , suggesting it may play an important role in myelopoiesis. JunB inactivation leads to early lethality in mice (Schorpp-Kistner et al., 1999) . To rescue the early lethality of JunB knock-out mice, viable JunB knock-out mice were generated by expressing JunB via the human ubiquitin promoter transgene (JunB
Ubi-junB) (Passegue et al., 2001) . Surprisingly, these mice gradually develop elevated levels of mature myeloid cells in the blood, spleen, bone marrow, and lymph nodes beginning at 4 months of age. Sixteen per cent of the mice progress from this chronic CML-like disease to a syndrome resembling blast crisis characterized by an expansion of immature myeloid cells. Clonal analysis of these leukemic cells will determine if JunB down-regulation directly leads to leukemia, or confers a predisposition to the development of leukemia. Symptom-free 1 ± 3-month-old mice express JunB in all hematopoietic lineages analysed. As the myeloproliferative disease progresses, JunB expression is down regulated or lost in myeloid cells. This suggests that down-regulation or loss of JunB expression contributes to the myeloid cell expansion. To test this hypothesis, JunB de®cient fetal liver cells were used to reconstitute lethally irradiated mice. The reconstituted mice develop a myeloproliferative disorder similar to that in JunB
Ubi-junB transgenic mice (Passegue et al., 2001 ). These results demonstrate that loss of JunB expression is a pathogenetic factor in myeloid leukemogenesis. It remains to be determined if downregulation of JunB transcription or activity is an etiological factor in human CML.
JunB expression inhibits cyclin D1 function by activating P16
INK4a (Bakiri et al., 2000; Passegue and Wagner, 2000) Cyclin D1 over-expression complements BCR ± ABL induced transformation . Therefore, cyclin D1 up-regulation may be a common signaling event in myeloid leukemogenesis induced by both BCR ± ABL expression and loss of JunB activity.
Although JunB
7/7
Ubi-junB transgenic mice lose JunB expression in the myeloid compartment during disease progression, JunB expression is maintained in T cells, B cells and erythrocytes. This suggests that loss of JunB expression in HSCs is not required for the induction of the myeloproliferative disorder. Further, it suggests that a genetic lesion restricted to myeloid progenitors and their progeny can induce a CML-like disease. As BCR ± ABL is expressed in all hematpoietic lineages (except NK cells) of chronic phase CML patients, this raises the question of whether targeting its expression exclusively to the common myeloid progenitor (CMP) (Akashi et al., 2000) and its progeny in animal model systems leads to the development of a CML-like disease. This will also provide information as to the involvement of the HSC in CML beyond that of the cellular origin/target.
ES in vitro dierentiation system
One major obstacle in studying BCR ± ABL eects on the HSC is the rarity of this population in vivo. BCR ± ABL studies in vivo are complicated by the occurrence of cell autonomous as well as indirect eects of BCR ± ABL expression, often in multiple cell-types depending on the nature of transcriptional/ regulatory elements employed. We have modi®ed an ES in vitro dierentiation system by adding tetracycline-regulation to study the direct impact of BCR ± ABL on hematopoietic development (Era and .
We adapted an ES cell dierentiation system that speci®cally favors hematopoietic development (Nakano et al., 1994) . ES cells are induced to dierentiate on an M-CSF 7/7 stromal cell line (OP9) which preferentially supports dierentiation of myeloid and erythroid cells without an overproduction of macrophages. Up to 5 days of dierentiation, ES cells develop into hemangioblasts capable of forming hematopoietic and endothelial cells. At this stage, early hematopoietic cells begin to form and by day 7 ± 8 many hematopoietic progenitors are present. From day 8 ± 14, dierentiation proceeds generating mature myeloid and erythroid cells.
We investigated the eect of BCR ± ABL expression on immature and mature hematopoietic cell populations in this system by controlling the dose and timing of P210 expression via a Tet-regulatable promoter. P210 expression led to an expansion of early progenitors and mature myeloid cells with a concomitant reduction in the erythroid compartment (Era and . An acute 48 h exposure to P210 BCR ± ABL was sucient for the ampli®cation of progenitors, demonstrating that BCR ± ABL expression is necessary and sucient to expand hematopoietic progenitors. The cell expansion in response to BCR ± ABL expression was directly proportional to the dose of BCR ± ABL, with maximal P210 expression leading to a threefold increase in cell number over 2 days. The expansion of myeloid cells is reversible, demonstrating that sustained BCR ± ABL expression is required for its maintenance. Possible explanations for this BCR ± ABL induced cell expansion include an increase in cell cycling, resistance to apoptosis, or a delay in dierentiation. An increase in cell proliferation measured by BrdU uptake was observed during BCR ± ABL induction, but there was no dramatic change in the rate of apoptosis. Discordant hematopoietic maturation (Clarkson and Strife, 1993 ) is a feature in human cpCML which may underlie the frequent incidence of anemia resulting from a severe reduction in erythropoiesis, as well as the myeloid expansion. The discordant maturation hypothesis proposes that BCR ± ABL may aect growth responses by deregulating dierentiation programs of primitive hematopoietic cells. It remains to be seen if our observations in the ES-dierentiation system are associated with delayed maturation within critical hematopoietic populations.
Conclusion
Various animal model systems have demonstrated that BCR ± ABL expression is sucient to initiate the development of a variety of dierent leukemias. Targeting speci®c cell-types has been shown to be critical in determining the type of leukemia formed. The use of global promoters such as MT and murine bcr to drive P185 expression have generated leukemia models mimicking many features of human P185 B-ALL. Enriching for stem and progenitor cell populations expressing P210 by 5-FU bone marrow treatment or Tec promoter driven P210 transgenic expression have generated CML models. These models have utilized knock-out cells to genetically determine the requirement of pathways implicated in BCR ± ABL transformation. Thus far, many signaling pathways thought to be critical in BCR ± ABL oncogenesis (such as BCR, STAT5, IL-3, and GM ± CSF) have been shown to be dispensable for BCR ± ABL induced leukemogenesis. ICSBP and JunB knock-out mice develop a CML-like disease. Are there common signaling pathways operating in these and P210 leukemic mice?
In human Ph + leukemias, CML is overwhelmingly associated with P210 BCR ± ABL, while P185 is typically associated with B-ALL. However, BCR ± ABL mouse models have demonstrated that dierent forms of BCR ± ABL can generate a similar spectrum of leukemias. Despite this, these mouse models do show that P185 generates leukemia in mice at a faster rate compared to P210, consistent with the chronic indolent nature of CML. The Tet-regulatable P210 mouse model and ES in vitro dierentiation systems demonstrate that BCR ± ABL expression is necessary and sucient to deregulate hematopoietic development. Combining these systems will allow the identi®cation of critical hematopoietic populations directly aected by BCR ± ABL expression in vivo, as well as the eect, if any, of BCR ± ABL expression in the HSC. It is important to consider that CML originates in a single HSC. Although a single HSC can repopulate the hematopoietic system of a mouse (Osawa et al., 1996) , no one has yet reported the induction of a CML-like disease in mice inoculated with one or a few pure BCR ± ABL transduced or BCR ± ABL transgenic HSCs.
